{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-035859","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2026-09-08T13:15:54+00:00","discovered_at":"2026-09-08T13:17:00.309472+00:00","generated_at":"2026-09-08T13:17:12.855414+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Roivant's mosliciguat hits all PHocus endpoints: PVR -56.3%, 6MWD +35.2m in PH-ILD","bullets":["PHocus Phase 2 met primary endpoint: placebo-adjusted PVR reduction -56.3% (p<0.0001) at Week 16 in PH-ILD","Secondary endpoints met: 6MWD +35.2m (p=0.0027), NT-proBNP -53.2% (p=0.0002) at Week 16","Week 24 exploratory: 6MWD +52.7m, NT-proBNP -75.9% (both nominal p<0.0001)","Cough lower than placebo (12.1% vs 18.2%); favorable safety profile","Phase 3 PHrontier initiated (~375 patients); results presented at ERS 2026"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-035859","json":"https://secwatch.observer/filing/0001140361-26-035859.json","markdown":"https://secwatch.observer/filing/0001140361-26-035859.md","text":"https://secwatch.observer/filing/0001140361-26-035859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126035859/0001140361-26-035859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126035859/ef20081686_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T13:17:12.855414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}